Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours

被引:9
作者
Sonzogni-Desautels, K. [1 ]
Knapp, D. W. [2 ]
Sartin, E. [3 ]
Dore, M. [1 ]
机构
[1] Univ Montreal, Fac Med Vet, Dept Pathol & Microbiol, St Hyacinthe, PQ J2S 7C6, Canada
[2] Purdue Univ, Sch Vet Med, Dept Vet Clin Sci, W Lafayette, IN 47907 USA
[3] Auburn Univ, Coll Vet Med, Dept Pathobiol, Auburn, AL 36849 USA
基金
加拿大自然科学与工程研究理事会;
关键词
COX-2; deracoxib; dogs; mammary cancer; piroxicam; prostaglandins; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BREAST-CANCER INCIDENCE; URINARY-BLADDER CANCER; PROSTAGLANDIN E-2; COX-2; EXPRESSION; ASPIRIN USE; CELL-LINES; IN-VITRO; PIROXICAM; COLON;
D O I
10.1111/j.1476-5829.2010.00242.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Inhibition of cyclooxygenase-2 (COX-2) represents a possible avenue for the prevention and/or treatment of some cancers. Our goal was to compare the effect of a selective inhibitor of COX-2, deracoxib, and a COX-1 and -2 inhibitor, piroxicam, on the growth of canine mammary tumours in a murine model. CMT-9 was used to induce xenografts in nude mice. Mice were treated with piroxicam (0.6 mg kg(-1)), deracoxib (6 mg kg(-1)) or a control solution. Tumour volumes between 0 and 24 days post-treatment showed no significant difference between all groups. A second series of experiments was performed with a higher dose of piroxicam (0.9 mg kg(-1)). Tumour volumes between 14 and 21 days post-treatment were significantly smaller in piroxicam-treated mice compared with controls. These results demonstrate that COX inhibition reduced the growth of canine mammary cancer xenografts in mice, suggesting that COX inhibitors could have a positive effect in dogs.
引用
收藏
页码:161 / 171
页数:11
相关论文
共 64 条
  • [51] Seno H, 2002, CANCER RES, V62, P506
  • [52] The relationship between cyclooxygenase-2 expression and colorectal cancer
    Sheehan, KM
    Sheahan, K
    O'Donoghue, DP
    MacSweeney, F
    Conroy, RM
    Fitzgerald, DJ
    Murray, FE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (13): : 1254 - 1257
  • [53] Sheng HM, 1998, CANCER RES, V58, P362
  • [54] IDENTIFICATION OF A PHORBOL ESTER-REPRESSIBLE V-SRC-INDUCIBLE GENE
    SIMMONS, DL
    LEVY, DB
    YANNONI, Y
    ERIKSON, RL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (04) : 1178 - 1182
  • [55] Sorenmo K U, 2004, Vet Comp Oncol, V2, P13, DOI 10.1111/j.1476-5810.2004.00035.x
  • [56] Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO
  • [57] 2-B
  • [58] Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood
    Streppa, HK
    Jones, CJ
    Budsberg, SC
    [J]. AMERICAN JOURNAL OF VETERINARY RESEARCH, 2002, 63 (01) : 91 - 94
  • [59] Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk
    Terry, MB
    Gammon, MD
    Zhang, FF
    Tawfik, H
    Teitelbaum, SL
    Britton, JA
    Subbaramaiah, K
    Dannenberg, AJ
    Neugut, AI
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (20): : 2433 - 2440
  • [60] ASPIRIN USE AND REDUCED RISK OF FATAL COLON CANCER
    THUN, MJ
    NAMBOODIRI, MM
    HEATH, CW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) : 1593 - 1596